Pamabrom

Overview

Pamabrom is a diuretic that acts on the opioid receptor -nitric oxide (NO) -cyclic guanosine monophosphate (cGMP) -K + channel pathway. Pamabrom exerts peripheral antinociceptive activity by activating this pathway. The mechanism involves activating opioid receptors, promoting the release of nitric oxide, and then influencing cyclic guanosine monophosphate and K channels to produce an analgesic effect. Pamabrom is orally active and is mainly used in the research and treatment of premenstrual syndrome and primary dysmenorrhea [1].

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Endocrinology | Products > Signaling Pathways > Adenosine Receptor

Product Information

• Catalog No.: HY-17391
• CAS No.: 606-04-2
• Molecular Formula: C11H18BrN5O3
• Molecular Weight: 348.20
• Purity: 99.92%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.67 mg/mL (7.67 mM); Clear solution
• Availability: In-stock

Source

Original product source